Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy

Medicinal Research Reviews

Volumn 34, Issue 1, 2014, Pages 106-135

  Carvalho, Filipa S ^a,b   Burgeiro, Ana ^a,c   Garcia, Rita ^c   Moreno, António J ^b,c   Carvalho, Rui A ^a,b   Oliveira, Paulo J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cardiac metabolism; Doxorubicin; Mitochondria; Toxicity

Indexed keywords

DOXORUBICIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE;

ACUTE TOXICITY; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DEATH; CELL LOSS; CHRONIC TOXICITY; DNA DAMAGE; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART PERFORMANCE; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PHYSICAL ACTIVITY; RISK FACTOR;

CARDIAC METABOLISM; DOXORUBICIN; MITOCHONDRIA; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; DOXORUBICIN; ENERGY METABOLISM; HUMANS; MITOCHONDRIA, HEART; RATS;

EID: 84894765443     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21280     Document Type: Article

References (222)

1. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F. Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J 1969;3(5669):503-506.
2. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 1970;30(10):2572-2582.
3. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: The good, the bad and the ugly effect. Curr Med Chem 2009;16(25):3267-3285.
4. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54(Suppl 4):1-7.
5. Aubel-Sadron G, Londos-Gagliardi D. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 1984;66(5):333-352.
6. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339(13):900-905.
7. Villani F, Beretta G, Guindani A. Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals. Cancer Chemother Pharmacol 1979;3(4):249-251.
8. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62(6):873-879.
9. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010;115(2):155-162.
10. Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 2000;71(1-2):436-444.
11. Frishman WH, Sung HM, Yee HC, Liu LL, Keefe D, Einzig AI, Dutcher J. Cardiovascular toxicity with cancer chemotherapy. Curr Prob Cancer 1997;21(6):301-360.
12. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32(2):302-314.
13. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Safety 2000;22(4):263-302.
14. Pereira GC, Silva AM, Diogo CV, Carvalho FS, Monteiro P, Oliveira PJ. Drug-induced cardiac mitochondrial toxicity and protection: From doxorubicin to carvedilol. Curr Pharm Des 2011;17(20):2113-2129.
15. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. New Engl J Med 1979;300(6):278-283.
16. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55(12):2761-2765.
17. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 2004;109(25):3122-3131.
18. Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003;93(3):105-115.
19. Christiansen S, Autschbach R. Doxorubicin in experimental and clinical heart failure. Eur J Cardiothorac Surg 2006;30(4):611-616.
20. Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 2000;7(1):53-62.
21. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266(12):1672-1677.
22. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Saf 2000;22(4):263-302.
23. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. New Engl J Med 1995;332(26):1738-1743.
24. Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002;41(6):431-444.
25. Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 2006;33(3 Suppl 8):S8-S14.
26. Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: A systematic review. Ann Oncol 2002;13(4):503-512.
27. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23(34):8597-8605.
28. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anversa P. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010;121(2):276-292.
29. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351(2):145-153.
30. Zhu W, Shou W, Payne RM, Caldwell R, Field LJ. A mouse model for juvenile doxorubicin-induced cardiac dysfunction. Pediatr Res 2008;64(5):488-494.
31. Cusack BJ, Musser B, Gambliel H, Hadjokas NE, Olson RD. Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats. Cancer Chemother Pharmacol 2003;51(2):139-146.
32. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983;43(9):4467-4469.
33. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003;51(5):395-402.
34. Hong YM, Kim HS, Yoon HR. Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine. Pediatr Res 2002;51(2):249-255.
35. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: Mechanism and modulation. Mol Cell Biochem 2000;207(1-2):77-86.
36. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49(5):330-352.
37. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62(6):865-872.
38. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallace KB. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 2004;200(2):159-168.
39. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. J Mol Cell Cardiol 2006;41(3):389-405.
40. Unverferth DV, Magorien RD, Unverferth BP, Talley RL, Balcerzak SP, Baba N. Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep 1981;65(11-12):1093-1097.
41. Ascensao A, Magalhaes J, Soares JM, Ferreira R, Neuparth MJ, Marques F, Oliveira PJ, Duarte JA. Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am J Physiol Heart Circ Physiol 2005;289(2):H722-H731.
42. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56(2):185-229.
43. Sardao VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. Morphological alterations induced by doxorubicin on H9c2 myoblasts: Nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol 2009;25(3):227-243.
44. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 2008;6(4):278-281.
45. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57(7):727-741.
46. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, Szabo C, Pacher P. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009;296(5):H1466-H1483.
47. DeAtley SM, Aksenov MY, Aksenova MV, Jordan B, Carney JM, Butterfield DA. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 1999;134(1):51-62.
48. Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 2005;207(4):436-444.
49. Cardoso S, Santos RX, Carvalho C, Correia S, Pereira GC, Pereira SS, Oliveira PJ, Santos MS, Proenca T, Moreira PI. Doxorubicin increases the susceptibility of brain mitochondria to Ca(2+)-induced permeability transition and oxidative damage. Free Radic Biol Med 2008;45(10): 1395-1402.
50. Machado NG, Baldeiras I, Pereira GC, Pereira SP, Oliveira PJ. Sub-chronic administration of doxorubicin to Wistar rats results in oxidative stress and unaltered apoptotic signaling in the lung. Chem Biol Interact 2010;188(3):478-486.
51. Ascensao A, Lumini-Oliveira J, Machado NG, Ferreira RM, Goncalves IO, Moreira AC, Marques F, Sardao VA, Oliveira PJ, Magalhaes J. Acute exercise protects against calcium-induced cardiac mitochondrial permeability transition pore opening in doxorubicin-treated rats. Clin Sci (Lond) 2011;120(1):37-49.
52. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002;185(3):218-227.
53. Outomuro D, Grana DR, Azzato F, Milei J. Adriamycin-induced myocardial toxicity: New solutions for an old problem? Int J Cardiol 2007;117(1):6-15.
54. Kaiserova H, Simunek T, Sterba M, den Hartog GJ, Schroterova L, Popelova O, Gersl V, Kvasnickova E, Bast A. New iron chelators in anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007;7(2):145-150.
55. Quiles JL, Huertas JR, Battino M, Mataix J, Ramirez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002;180(1):79-95.
56. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 1980;65(1):128-135.
57. Li T, Danelisen I, Singal PK. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Cardiol 2002;232(1-2):19-26.
58. Thornalley PJ, Dodd NJ. Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. Biochem Pharmacol 1985;34(5):669-674.
59. Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 1983;43(10):4543-4551.
60. Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 1986;261(7): 3068-3074.
61. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983;43(2):460-472.
62. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA, Jr., Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997;36(38):11293-11297.
63. Demant EJ, Jensen PK. Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex. Eur J Biochem 1983;132(3):551-556.
64. Marcillat O, Zhang Y, Davies KJ. Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochem J 1989;259(1):181-189.
65. Yoon SB, Kajiyama K, Hino Y, Sugiyama M, Ogura R. Effect of adriamycin on lipid peroxide, glutathione peroxidase and respiratory responses of mitochondria from the heart, liver and kidney. Kurume Med J 1983;30(1):1-4.
66. Parker MA, King V, Howard KP. Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers. Biochim Biophys Acta 2001;1514(2):206-216.
67. Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert JM. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 1990;35(2-3):247-257.
68. Claypool SM, Koehler CM. The complexity of cardiolipin in health and disease. Trends Biochem Sci 2012;37(1):32-41.
69. Goormaghtigh E, Huart P, Brasseur R, Ruysschaert JM. Mechanism of inhibition of mitochondrial enzymatic complex I-III by adriamycin derivatives. Biochim Biophys Acta 1986;861(1):83-94.
70. Oliveira PJ, Wallace KB. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats-Relevance for mitochondrial dysfunction. Toxicology 2006;220(2-3):160-168.
71. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001;61(2):771-777.
72. Pereira GC, Pereira SP, Pereira CV, Lumini JA, Magalhaes J, Ascensao A, Santos MS, Moreno AJ, Oliveira PJ. Mitochondrionopathy phenotype in doxorubicin-treated wistar rats depends on treatment protocol and is cardiac-specific. PLoS One 2012;7(6):e38867.
73. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 2007;23(1):15-25.
74. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002;62(16):4592-4598.
75. Kuznetsov AV, Margreiter R, Amberger A, Saks V, Grimm M. Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochim Biophys Acta 2011;1813(6):1144-1152.
76. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001;61(2):771-777.
77. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012;149(7):1536-1548.
78. Rasola A, Bernardi P. Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium 2011;50(3):222-233.
79. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005;434(7033):652-658.
80. Baines CP. The molecular composition of the mitochondrial permeability transition pore. J Mol Cell Cardiol 2009;46(6):850-857.
81. Javadov S, Karmazyn M, Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther 2009;330(3):670-678.
82. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004;427(6973):461-465.
83. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol 2007;9(5):550-555.
84. Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 2009;46(6):821-831.
85. Leung AW, Varanyuwatana P, Halestrap AP. The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J Biol Chem 2008;283(39):26312-26323.
86. Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol 2009;104(2):181-188.
87. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 2009;1787(11):1402-1415.
88. Liu J, Mao W, Ding B, Liang CS. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 2008;295(5):H1956-H1965.
89. Oliveira PJ, Santos MS, Wallace KB. Doxorubicin-induced thiol-dependent alteration of cardiac mitochondrial permeability transition and respiration. Biochemistry (Mosc) 2006;71(2):194-199.
90. Broekemeier KM, Dempsey ME, Pfeiffer DR. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 1989;264(14):7826-7830.
91. McStay GP, Clarke SJ, Halestrap AP. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J 2002;367(Pt 2):541-548.
92. Halestrap AP, Woodfield KY, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem 1997;272(6):3346-3354.
93. Tokarska-Schlattner M, Wallimann T, Schlattner U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biol 2006;329(9):657-668.
94. Berthiaume JM, Wallace KB. Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovasc Toxicol 2007;7(3):178-191.
95. Richard C, Ghibu S, Delemasure-Chalumeau S, Guilland JC, Des Rosiers C, Zeller M, Cottin Y, Rochette L, Vergely C. Oxidative stress and myocardial gene alterations associated with doxorubicin-induced cardiotoxicity in rats persist for 2 months after treatment cessation. J Pharmacol Exp Ther 2011;339(3):807-814.
96. Ashley N, Poulton J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun 2009;378(3):450-455.
97. Adachi K, Fujiura Y, Mayumi F, Nozuhara A, Sugiu Y, Sakanashi T, Hidaka T, Toshima H. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun 1993;195(2):945-951.
98. Ellis CN, Ellis MB, Blakemore WS. Effect of adriamycin on heart mitochondrial DNA. Biochem J 1987;245(1):309-312.
99. Hixon SC, Ellis CN, Daugherty JP. Heart mitochondrial DNA synthesis: Preferential inhibition by adriamycin. J Mol Cell Cardiol 1981;13(9):855-860.
100. Serrano J, Palmeira CM, Kuehl DW, Wallace KB. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta 1999;1411(1):201-205.
101. Palmeira CM, Serrano J, Kuehl DW, Wallace KB. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta 1997;1321(2):101-106.
102. Lebrecht D, Kirschner J, Geist A, Haberstroh J, Walker UA. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy. Cardiovasc Pathol 2010;19(5):e167-e174.
103. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003;108(19):2423-2429.
104. Sardao VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol 2009;64(4):811-827.
105. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEB J 1997;11(12):931-936.
106. Van Vleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 1980;99(1):13-42.
107. Yamanaka S, Tatsumi T, Shiraishi J, Mano A, Keira N, Matoba S, Asayama J, Fushiki S, Fliss H, Nakagawa M. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol 2003;41(5):870-878.
108. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004;37(4):837-846.
109. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197(4299):165-167.
110. Mimnaugh EG, Siddik ZH, Drew R, Sikic BI, Gram TE. The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. Toxicol Appl Pharmacol 1979;49(1):119-126.
111. Berthiaume JM, Oliveira PJ, Fariss MW, Wallace KB. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 2005;5(3):257-267.
112. Zhang X, Peng X, Yu W, Hou S, Zhao Y, Zhang Z, Huang X, Wu K. Alpha-tocopheryl succinate enhances doxorubicin-induced apoptosis in human gastric cancer cells via promotion of doxorubicin influx and suppression of doxorubicin efflux. Cancer Lett 2011;307(2):174-181.
113. Liu QY, Tan BK. Dietary fish oil and vitamin E enhance doxorubicin effects in P388 tumor-bearing mice. Lipids 2002;37(6):549-556.
114. Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999;65(12):1265-1274.
115. Machado V, Cabral A, Monteiro P, Goncalves L, Providencia LA. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol 2008;27(10):1277-1296.
116. Oliveira PJ, Rolo AP, Sardao VA, Monteiro P, Goncalves L, Providencia LA, Palmeira CM, Moreno AJ. Advantages in the use of carvedilol versus propranolol for the protection of cardiac mitochondrial function. Rev Port Cardiol 2004;23(10):1291-1298.
117. Oliveira PJ, Santos DJ, Moreno AJ. Carvedilol inhibits the exogenous NADH dehydrogenase in rat heart mitochondria. Arch Biochem Biophys 2000;374(2):279-285.
118. Nohl H. Demonstration of the existence of an organo-specific NADH dehydrogenase in heart mitochondria. Eur J Biochem 1987;169(3):585-591.
119. Noguchi N, Nishino K, Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem Pharmacol 2000;59(9):1069-1076.
120. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48(11):2258-2262.
121. Hasinoff BB, Herman EH. Dexrazoxane: How it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol 2007;7(2):140-144.
122. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15(4):1318-1332.
123. Kolaric K, Bradamante V, Cervek J, Cieslinska A, Cisarz-Filipcak E, Denisov LE, Donat D, Drosik K, Gershanovic M, Hudziec P, Jelic S, Jurga L, Kalasiewicz M, Kowgird L, Kozacka M, Lichinitzer M, Machalski M, Mechl Z, Odintsov S, Pawlicki M, Rubach D, Roth A, Stabuc B, Tomczak J, Utracka B, Zborzil J, Rogan J. A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology 1995;52(3):251-255.
124. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, Slater W, Blum R, Muggia F. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319(12):745-752.
125. Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, Bast A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 1994;26(9):1179-1185.
126. Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 2003;35(11):1469-1479.
127. Kaiserova H, den Hartog GJ, Simunek T, Schroterova L, Kvasnickova E, Bast A. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin. Br J Pharmacol 2006;149(7):920-930.
128. Liu XW, Chen ZG, Chua CC, Ma YS, Youngberg GA, Hamdy R, Chua BHL. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2002;283(1):H254-H263.
129. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJF. Antagonistic effect of the cardioprotector (+)-1, 2-bis(3, 5-dioxopiperazinyl-1-Yl)propane (Icrf-187) on DNA breaks and cytotoxicity induced by the topoisomerase-Ii directed drugs daunorubicin and etoposide (Vp-16). Biochem Pharmacol 1993;46(3):389-393.
130. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997;15(4):1333-1340.
131. Jirkovsky E, Popelova O, Krivakova-Stankova P, Vavrova A, Hroch M, Haskova P, Brcakova-Dolezelova E, Micuda S, Adamcova M, Simunek T, Cervinkova Z, Gersl V, Sterba M. Chronic anthracycline cardiotoxicity: Molecular and functional analysis with focus on Nrf2 and mitochondrial biogenesis pathways. J Pharmacol Exp Ther 2012;343(2):468-478.
132. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 1997;100(6):1501-1506.
133. Xiong Y, Liu X, Lee CP, Chua BH, Ho YS. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radic Biol Med 2006;41(1):46-55.
134. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 1996;271(21):12610-12616.
135. Go YM, Jones DP. Cysteine/cystine redox signaling in cardiovascular disease. Free Radic Biol Med 2011;50(4):495-509.
136. Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008;295(4):C849-C868.
137. Poljsak B, Milisav I. The neglected significance of "antioxidative stress". Oxid Med Cell Longev 2012;2012:480895.
138. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: Cardioprotection by Mito-Q. Biophys J 2009;96(4):1388-1398.
139. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000;275(43):33585-33592.
140. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009;57(6):435-445.
141. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000;60(7):1789-1792.
142. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp 2009;57(6):435-445.
143. Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: Role of inhibition of ceramide generation. FASEB J 1999;13(12):1501-1510.
144. Yamaoka M, Yamaguchi S, Suzuki T, Okuyama M, Nitobe J, Nakamura N, Mitsui Y, Tomoike H. Apoptosis in rat cardiac myocytes induced by Fas ligand: Priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 2000;32(6):881-889.
145. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, Field LJ. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009;119(1):99-106.
146. Yoshida M, Shiojima I, Ikeda H, Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 2009;47(5):698-705.
147. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997;275(5296):90-94.
148. Liu X, Chua CC, Gao J, Chen Z, Landy CL, Hamdy R, Chua BH. Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 2004;286(3):H933-H939.
149. Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T, Suzuki YJ. Anthracycline-induced suppression of GATA-4 transcription factor: Implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 2003;63(2):368-377.
150. Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE, Piantadosi CA. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest 2007;117(12):3730-3741.
151. Fan GC, Zhou X, Wang X, Song G, Qian J, Nicolaou P, Chen G, Ren X, Kranias EG. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circ Res 2008;103(11):1270-1279.
152. Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T, Yamaguchi I. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 2006;101(2):151-158.
153. Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 2002;1588(1):94-101.
154. Kunisada K, Tone E, Negoro S, Nakaoka Y, Oshima Y, Osugi T, Funamoto M, Izumi M, Fujio Y, Hirota H, Yamauchi-Takihara K. Bcl-xl reduces doxorubicin-induced myocardial damage but fails to control cardiac gene downregulation. Cardiovasc Res 2002;53(4):936-943.
155. Youn HJ, Kim HS, Jeon MH, Lee JH, Seo YJ, Lee YJ. Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol Cell Biochem 2005;270(1-2):13-19.
156. Jang YM, Kendaiah S, Drew B, Phillips T, Selman C, Julian D, Leeuwenburgh C. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett 2004;577(3):483-490.
157. Velez JM, Miriyala S, Nithipongvanitch R, Noel T, Plabplueng CD, Oberley T, Jungsuwadee P, Van Remmen H, Vore M, St Clair DK. p53 regulates oxidative stress-mediated retrograde signaling: A novel mechanism for chemotherapy-induced cardiac injury. PLoS One 2011;6(3):e18005.
158. Feridooni T, Hotchkiss A, Remley-Carr S, Saga Y, Pasumarthi KB. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS One 2011;6(7):e22801.
159. Chua CC, Liu X, Gao J, Hamdy RC, Chua BH. Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am J Physiol Heart Circ Physiol 2006;290(6):H2606-H2613.
160. Kajihara H, Yokozaki H, Yamahara M, Kadomoto Y, Tahara E. Anthracycline induced myocardial damage. An analysis of 16 autopsy cases. Pathol Res Pract 1986;181(4):434-441.
161. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000;60(7):1789-1792.
162. Bernaba BN, Chan JB, Lai CK, Fishbein MC. Pathology of late-onset anthracycline cardiomyopathy. Cardiovasc Pathol 2010;19(5):308-311.
163. Dazzi H, Kaufmann K, Follath F. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996. Ann Oncol 2001;12(7):963-966.
164. Spallarossa P, Altieri P, Aloi C, Garibaldi S, Barisione C, Ghigliotti G, Fugazza G, Barsotti A, Brunelli C. Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol 2009;297(6):H2169-H2181.
165. Maejima Y, Adachi S, Ito H, Hirao K, Isobe M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 2008;7(2):125-136.
166. Dimitrakis P, Romay-Ogando MI, Timolati F, Suter TM, Zuppinger C. Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. Cell Tissue Res 2012;350(2):361-372.
167. Lu L, Wu W, Yan J, Li X, Yu H, Yu X. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int J Cardiol 2009;134(1):82-90.
168. Kaji A, Zhang Y, Nomura M, Bode AM, Ma WY, She QB, Dong Z. Pifithrin-alpha promotes p53-mediated apoptosis in JB6 cells. Mol Carcinog 2003;37(3):138-148.
169. Eidenschink AB, Schroter G, Muller-Weihrich S, Stern H. Myocardial high-energy phosphate metabolism is altered after treatment with anthracycline in childhood. Cardiol Young 2000;10(6):610-617.
170. Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T, Schlattner U. Acute toxicity of doxorubicin on isolated perfused heart: Response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol 2005;289(1):H37-H47.
171. Tokarska-Schlattner M, Wallimann T, Schlattner U. Multiple interference of anthracyclines with mitochondrial creatine kinases: Preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol Pharmacol 2002;61(3):516-523.
172. Gratia S, Kay L, Potenza L, Seffouh A, Novel-Chate V, Schnebelen C, Sestili P, Schlattner U, Tokarska-Schlattner M. Inhibition of AMPK signalling by doxorubicin: At the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovasc Res 2012;95(3):290-299.
173. Kockskamper J, Zima AV, Blatter LA. Modulation of sarcoplasmic reticulum Ca2+ release by glycolysis in cat atrial myocytes. J Physiol 2005;564(Pt 3):697-714.
174. + exchange activity in guinea pig ventricular myocytes. Mol Cell Biochem 2001;217(1-2):153-161.
175. Abdel-aleem S, El-Merzabani MM, Sayed-Ahmed M, Taylor DA, Lowe JE. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol 1997;29(2):789-797.
176. Brady LJ, Brady PS. Hepatic and cardiac carnitine palmitoyltransferase activity. Effects of adriamycin and galactosamine. Biochem Pharmacol 1987;36(20):3419-3423.
177. Carvalho RA, Sousa RP, Cadete VJ, Lopaschuk GD, Palmeira CM, Bjork JA, Wallace KB. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology 2010;270(2-3):92-98.
178. Hrelia S, Fiorentini D, Maraldi T, Angeloni C, Bordoni A, Biagi PL, Hakim G. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta 2002;1567(1-2):150-156.
179. Tokarska-Schlattner M, Lucchinetti E, Zaugg M, Kay L, Gratia S, Guzun R, Saks V, Schlattner U. Early effects of doxorubicin in perfused heart: Transcriptional profiling reveals inhibition of cellular stress response genes. Am J Physiol Regul Integr Comp Physiol 2010;298(4):R1075-R1088.
180. Andreadou I, Papaefthimiou M, Zira A, Constantinou M, Sigala F, Skaltsounis AL, Tsantili-Kakoulidou A, Iliodromitis EK, Kremastinos DT, Mikros E. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. NMR Biomed 2009;22(6):585-592.
181. Reuter SE, Evans AM. Carnitine and acylcarnitines: Pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet 2012;51(9):553-572.
182. Luo X, Reichetzer B, Trines J, Benson LN, Lehotay DC. L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats. Free Radic Biol Med 1999;26(9-10):1158-1165.
183. Mijares A, Lopez JR. L-carnitine prevents increase in diastolic [CA2+] induced by doxorubicin in cardiac cells. Eur J Pharmacol 2001;425(2):117-120.
184. Sayed-Ahmed MM, Al-Shabanah OA, Hafez MM, Aleisa AM, Al-Rejaie SS. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol 2010;640(1-3):143-149.
185. Yoon HR, Hong YM, Boriack RL, Bennett MJ. Effect of L-carnitine supplementation on cardiac carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats. Pediatr Res 2003;53(5):788-792.
186. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90(1):207-258.
187. Bar J, Davidi O, Goshen Y, Hod M, Yaniv I, Hirsch R. Pregnancy outcome in women treated with doxorubicin for childhood cancer. Am J Obstet Gynecol 2003;189(3):853-857.
188. Davis LE, Brown CE. Peripartum heart failure in a patient treated previously with doxorubicin. Obstet Gynecol 1988;71(3 Pt 2):506-508.
189. Katz A, Goldenberg I, Maoz C, Thaler M, Grossman E, Rosenthal T. Peripartum cardiomyopathy occurring in a patient previously treated with doxorubicin. Am J Med Sci 1997;314(6):399-400.
190. Green DM, Fiorello A, Zevon MA, Hall B, Seigelstein N. Birth defects and childhood cancer in offspring of survivors of childhood cancer. Arch Pediatr Adolesc Med 1997;151(4):379-383.
191. Ascensao A, Oliveira PJ, Magalhaes J. Exercise as a beneficial adjunct therapy during doxorubicin treatment-Role of mitochondria in cardioprotection. Int J Cardiol 2012;156(1):4-10.
192. Hayward R, Lien CY, Jensen BT, Hydock DS, Schneider CM. Exercise training mitigates anthracycline-induced chronic cardiotoxicity in a juvenile rat model. Pediatr Blood Cancer 2011.
193. Black P, Gutjahr P, Stopfkuchen H. Physical performance in long-term survivors of acute leukaemia in childhood. Eur J Pediatr 1998;157(6):464-467.
194. Steinherz L, Steinherz P. Delayed cardiac toxicity from anthracycline therapy. Pediatrician 1991;18(1):49-52.
195. Chugun A, Temma K, Oyamada T, Suzuki N, Kamiya Y, Hara Y, Sasaki T, Kondo H, Akera T. Doxorubicin-induced late cardiotoxicity: Delayed impairment of Ca2+-handling mechanisms in the sarcoplasmic reticulum in the rat. Can J Physiol Pharmacol 2000;78(4):329-338.
196. Monti E, Prosperi E, Supino R, Bottiroli G. Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. Anticancer Res 1995;15(1): 193-197.
197. Sugiyama S, Yamada K, Hayakawa M, Ozawa T. Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial function in rat hearts; liposome-encapsulated doxorubicin or combination therapy with antioxidant. Biochem Mol Biol Int 1995;36(5):1001-1007.
198. Villani F, Galimberti M, Monti E, Piccinini F, Poggi P, Lanza E, Rozza A, Favalli L. Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats. Pharmacol Res 1991;23(2): 195-202.
199. Perletti G, Monti E, Paracchini L, Piccinini F. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity. Arch Int Pharmacodyn Ther 1989;302:280-289.
200. Ramires PR, Ji LL. Glutathione supplementation and training increases myocardial resistance to ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 2001;281(2):H679-H688.
201. Venditti P, DiMeo S. Antioxidants, tissue damage, and endurance in trained and untrained young male rats. Arch Biochem Biophys 1996;331(1):63-68.
202. Powers SK, Demirel HA, Vincent HK, Coombes JS, Naito H, Hamilton KL, Shanely RA, Jessup J. Exercise training improves myocardial tolerance to in vivo ischemia-reperfusion in the rat. Am J Physiol 1998;275(5 Pt 2):R1468-R1477.
203. Lumini JA, Magalhaes J, Oliveira PJ, Ascensao A. Beneficial effects of exercise on muscle mitochondrial function in diabetes mellitus. Sports Med 2008;38(9):735-750.
204. Ascensao A, Magalhaes J, Soares J, Ferreira R, Neuparth M, Marques F, Oliveira J, Duarte J. Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int J Cardiol 2005;100(3):451-460.
205. Wonders KY, Hydock DS, Schneider CM, Hayward R. Acute exercise protects against doxorubicin cardiotoxicity. Integr Cancer Ther 2008;7(3):147-154.
206. Taylor RP, Harris MB, Starnes JW. Acute exercise can improve cardioprotection without increasing heat shock protein content. Am J Physiol 1999;276(3 Pt 2):H1098-H1102.
207. Taylor RP, Olsen ME, Starnes JW. Improved postischemic function following acute exercise is not mediated by nitric oxide synthase in the rat heart. Am J Physiol Heart Circ Physiol 2007;292(1):H601-H607.
208. Starnes JW, Taylor RP, Park Y. Exercise improves postischemic function in aging hearts. Am J Physiol Heart Circ Physiol 2003;285(1):H347-H351.
209. Brown DA, Lynch JM, Armstrong CJ, Caruso NM, Ehlers LB, Johnson MS, Moore RL. Susceptibility of the heart to ischaemia-reperfusion injury and exercise-induced cardioprotection are sex-dependent in the rat. J Physiol 2005;564(Pt 2):619-630.
210. Swain DP, Franklin BA. Is there a threshold intensity for aerobic training in cardiac patients? Med Sci Sports Exerc 2002;34(7):1071-1075.
211. Ascensao A, Magalhaes J, Soares J, Oliveira J, Duarte JA. Exercise and cardiac oxidative stress. Rev Port Cardiol 2003;22(5):651-678.
212. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF, Jr., Smith SC, Jr., Stone NJ, Taubert KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106(3):388-391.
213. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK, American Heart Association Council on Clinical Cardiology Subcommittee on Exercise R, Prevention, American Heart Association Council on Nutrition PA, Metabolism Subcommittee on Physical A. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107(24):3109-3116.
214. Chicco AJ, Schneider CM, Hayward R. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol 2006;47(2):182-189.
215. Chen K, Xu X, Kobayashi S, Timm D, Jepperson T, Liang Q. Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms. J Biol Chem 2011;286(25):21993-22006.
216. Mitra MS, Donthamsetty S, White B, Latendresse JR, Mehendale HM. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol Appl Pharmacol 2007;225(1):90-101.
217. Kawaguchi T, Takemura G, Kanamori H, Takeyama T, Watanabe T, Morishita K, Ogino A, Tsujimoto A, Goto K, Maruyama R, Kawasaki M, Mikami A, Fujiwara T, Fujiwara H, Minatoguchi S. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc Res 2012;96(3):456-465.
218. Bardi E, Bobok I, V Oláh A, Kappelmayer J, Kiss C. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. Pathol Oncol Res 2007;13(3):249-253.
219. Todorova VK, Kaufmann Y, Hennings L, Klimberg VS. Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats. J Nutr 2010;140(1):44-48.
220. Todorova VK, Kaufmann Y, Hennings LJ, Klimberg VS. Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats. Cancer Chemother Pharmacol 2010;66(2):315-323.
221. Dresdale AR, Barr LH, Bonow RO, Mathisen DJ, Myers CE, Schwartz DE, d'Angelo T, Rosenberg SA. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol 1982;5(6):657-663.
222. Lebrecht D, Kirschner J, Geist A, Haberstroh J, Walker Ua. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy. Cardiovasc Pathol 2010;19(5):167-174.